To view associated reagents, ancillaries and bulks, please visit the Roche Tissue Diagnostics reagent catalog.
A leader in breast cancer diagnostics, Roche Diagnostics offers numerous cancer diagnostic assays that enable pathology labs to deliver accurate results with confidence. We provide a robust menu of breast cancer diagnostic tools. Our portfolio of products delivers the high sensitivity and specificity you need from your assays.
Experts predict over 500,000 deaths annually due to breast cancer, making it a leading cause of death in women. In developed countries breast cancer related mortality has declined, in part due to therapeutic advances and evolution of biomarkers. For example, Immunohistochemistry (IHC) analysis and in situ hybridization (ISH) analysis provide important information related to tumor biology, help profile types of breast cancer and may improve treatment decisions.
With proven accuracy, VENTANA breast cancer diagnostic assays help you identify patients other assays can miss – so you can deliver the right test, with clinical confidence in the shortest possible time.
Specific and sensitive rabbit monoclonal antibodies, best-in-class probes, and powerful detection systems help you diagnose precisely and confidently.
Our comprehensive breast cancer workflow solution delivers fully-automated assays on market-leading platforms, with digital pathology and workflow solutions that free resources, reduce labor costs, and reduce time to results.
The use of pre-diluted PATHWAY HER2 (4B5),14 in combination with the fully automated VENTANA BenchMark IHC/ISH slide staining instrument, standardizes all IHC processes from baking through staining, and reduces the possibility of human error. It also minimized inherent variability resulting from individual reagent dilution and other processes found in manual and semi-automated IHC methods.
Using the right test to determine PD-L1 status for immunotherapy options is important. The VENTANA PD-L1 (SP142) Assay gives you the confidence to reliably identify triple-negative breast cancer (TNBC) patients eligible for TECENTRIQ.®11,12
The novel VENTANA PD-L1 (SP142) Assay is easy to score and the first with FDA-approval to evaluate breast cancer patients for PD-L1 expression using immune cell staining and scoring within the tumor microenvironment. The assay provides you with information that multidisciplinary teams need to guide immunotherapy decisions in TNBC. The VENTANA PD-L1 (SP142) Assay: